FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2408874524> ?p ?o ?g. }

• W2408874524 abstract "Background Patients with rheumatoid arthritis (RA) are reportedly at higher risk of developing metabolic syndrome because of the high concentration of tumor necrosis factor alpha in their sera. Sarcopenia is a component of metabolic syndrome; therefore, sarcopenia in patients with RA is thought to be related to RA disease activity.Objectives We conducted a cross-sectional study to evaluate the relationship among skeletal muscle volume, disease activity, and insulin resistance, using the data in 2013 from TOMORROW study.Methods In this study, we performed a sub-analysis of 2013 data in the TOMORROW study (UMIN: 000003876). This prospective cohort study examined several risk factors for osteoporosis and metabolic syndrome in patients with RA. The participants in the study comprised 202 patients with RA (109 patients receiving biological disease-modifying antirheumatic drugs [bDMARDs]) and 202 age- and sex-matched healthy volunteers (collected through mass media as controls). All participants completed a self-administered questionnaire on their general health status to provide baseline data. Laboratory data and anthropometric parameters were also collected. Body composition was determined by whole-body dual X-ray absorptiometry. A cross-sectional analysis of the data obtained from the cohort study in 2013 was performed in the present study. The relationship among sarcopenia, lipid metabolism, and insulin resistance was analyzed. Sarcopenia was defined as an appendicular skeletal muscle mass index (ASMI) of <5.46 kg/m2 in females and <6.87 kg/m2 in males. The ASMI was calculated as the patient's appendicular lean body mass divided by the square of the patient's height.Results Sarcopenia was more apparent in patients with RA (6.14 kg/m2) than in controls (6.55 kg/m2) (p<0.001), especially in patients with RA treated with bDMARDs (tumor necrosis factor inhibitor, p=0.004; tocilizumab or abatacept, p<0.001) ([Fig][1]). Insulin resistance as expressed by the homeostasis model assessment ratio (HOMA-R) was significantly higher in patients with RA treated with tocilizumab or abatacept (1.38) than in controls (0.93) (p=0.019). Regression correlation analysis among patients with RA revealed a strong and significant correlation between the ASMI and body mass index (R =0.553; p<0.0001) and between the HOMA-R and body mass index (R =0.304, p<0.0001). There was a significant but weak relationship between the ASMI and Disease Activity Score 28 (R = –0.196, p=0.0064) and between the ASMI and HOMA-R (R =0.145, p=0.0447).![Figure][2] Conclusions In this study, we showed that patients with greater RA disease activity who were receiving bDMARDs had lower muscle volume. Additionally, insulin resistance was significantly lower in patients with RA treated with bDMARDs other than tumor necrosis factor inhibitor. According to these results, patients with RA are more likely to have sarcopenia caused by metabolic syndrome. Because of the resultant frailty of these patients, sarcopenia should be taken into account at the time of starting prohibiting falling, subsequently expected fractures.Disclosure of Interest K. Inui: None declared, T. Koike Grant/research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, M. Tada: None declared, Y. Sugioka: None declared, K. Mamoto: None declared, T. Okano: None declared, H. Nakamura Grant/research support from: Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Nippon Zoki Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co.,Ltd., Takeda Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co.,Inc., Ono Pharmaceutical Co., Ltd., Osteopharma Inc., Teijin Pharma Ltd., Asahi Kasei Pharma Co. [1]: #F1 [2]: pending:yes" @default.
• W2408874524 created "2016-06-24" @default.
• W2408874524 creator A5048478528 @default.
• W2408874524 creator A5055893822 @default.
• W2408874524 creator A5059847055 @default.
• W2408874524 creator A5074232917 @default.
• W2408874524 creator A5074923100 @default.
• W2408874524 creator A5086343918 @default.
• W2408874524 creator A5091382070 @default.
• W2408874524 date "2015-06-01" @default.
• W2408874524 modified "2023-09-26" @default.
• W2408874524 title "AB0359 Sarcopenia is Apparent in Patients with Rheumatoid Arthritis, Especially Those Treated with Biologics -Tomorrow Study-" @default.
• W2408874524 doi "https://doi.org/10.1136/annrheumdis-2015-eular.1221" @default.
• W2408874524 hasPublicationYear "2015" @default.
• W2408874524 type Work @default.
• W2408874524 sameAs 2408874524 @default.
• W2408874524 citedByCount "0" @default.
• W2408874524 crossrefType "journal-article" @default.
• W2408874524 hasAuthorship W2408874524A5048478528 @default.
• W2408874524 hasAuthorship W2408874524A5055893822 @default.
• W2408874524 hasAuthorship W2408874524A5059847055 @default.
• W2408874524 hasAuthorship W2408874524A5074232917 @default.
• W2408874524 hasAuthorship W2408874524A5074923100 @default.
• W2408874524 hasAuthorship W2408874524A5086343918 @default.
• W2408874524 hasAuthorship W2408874524A5091382070 @default.
• W2408874524 hasConcept C120863210 @default.
• W2408874524 hasConcept C126322002 @default.
• W2408874524 hasConcept C147583825 @default.
• W2408874524 hasConcept C2776214593 @default.
• W2408874524 hasConcept C2777575956 @default.
• W2408874524 hasConcept C2780221984 @default.
• W2408874524 hasConcept C2780578515 @default.
• W2408874524 hasConcept C511355011 @default.
• W2408874524 hasConcept C71924100 @default.
• W2408874524 hasConcept C72563966 @default.
• W2408874524 hasConceptScore W2408874524C120863210 @default.
• W2408874524 hasConceptScore W2408874524C126322002 @default.
• W2408874524 hasConceptScore W2408874524C147583825 @default.
• W2408874524 hasConceptScore W2408874524C2776214593 @default.
• W2408874524 hasConceptScore W2408874524C2777575956 @default.
• W2408874524 hasConceptScore W2408874524C2780221984 @default.
• W2408874524 hasConceptScore W2408874524C2780578515 @default.
• W2408874524 hasConceptScore W2408874524C511355011 @default.
• W2408874524 hasConceptScore W2408874524C71924100 @default.
• W2408874524 hasConceptScore W2408874524C72563966 @default.
• W2408874524 hasLocation W24088745241 @default.
• W2408874524 hasOpenAccess W2408874524 @default.
• W2408874524 hasPrimaryLocation W24088745241 @default.
• W2408874524 hasRelatedWork W2322456620 @default.
• W2408874524 hasRelatedWork W2326713497 @default.
• W2408874524 hasRelatedWork W2358879199 @default.
• W2408874524 hasRelatedWork W2408914282 @default.
• W2408874524 hasRelatedWork W2410594325 @default.
• W2408874524 hasRelatedWork W2754034395 @default.
• W2408874524 hasRelatedWork W2754134033 @default.
• W2408874524 hasRelatedWork W2755129016 @default.
• W2408874524 hasRelatedWork W2756338645 @default.
• W2408874524 hasRelatedWork W2901764611 @default.
• W2408874524 hasRelatedWork W2910037607 @default.
• W2408874524 hasRelatedWork W2946929194 @default.
• W2408874524 hasRelatedWork W2947106189 @default.
• W2408874524 hasRelatedWork W2947944584 @default.
• W2408874524 hasRelatedWork W2950191215 @default.
• W2408874524 hasRelatedWork W2950628140 @default.
• W2408874524 hasRelatedWork W2952336455 @default.
• W2408874524 hasRelatedWork W3029527566 @default.
• W2408874524 hasRelatedWork W3035345130 @default.
• W2408874524 hasRelatedWork W3165113086 @default.
• W2408874524 isParatext "false" @default.
• W2408874524 isRetracted "false" @default.
• W2408874524 magId "2408874524" @default.
• W2408874524 workType "article" @default.